Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Concerns about omissions in the data presented

被引：0
|
作者：
Kennedy, RD [1 ]
Cuthbert, RG [1 ]
Kettle, PJ [1 ]
Morris, TCM [1 ]
机构：
[1] Queens Univ Belfast, Belfast City Hosp, Belfast, Antrim, North Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2001年 / 19卷 / 06期
关键词：
D O I：
10.1200/JCO.2001.19.6.1884
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1884 / 1884
页数：1
相关论文
共 50 条
  • [1] High-dose therapy for aggressive non-Hodgkin's lymphoma
    Pettengell, R
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1996, 56 (10): : 521 - 524
  • [2] Aggressive non-Hodgkin's lymphoma - Economics of high-dose therapy
    Beard, SM
    Wall, L
    Gaffney, L
    Sampson, F
    PHARMACOECONOMICS, 2004, 22 (04) : 207 - 224
  • [3] Dose escalation of high-dose cyclophosphamide and etoposide with high-dose doxorubicin (CDE) and filgrastim for poor-risk non-Hodgkin's lymphoma
    Juliusson, G
    Liliemark, J
    ANNALS OF ONCOLOGY, 1996, 7 (10) : 1037 - 1041
  • [4] Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center
    Bouabdallah, R
    Coso, D
    Costello, R
    Bardou, VJ
    Blaise, D
    Xerri, L
    Sainty, D
    Maraninchi, D
    Gastaut, JA
    BONE MARROW TRANSPLANTATION, 2000, 25 (01) : 35 - 40
  • [5] Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center
    R Bouabdallah
    D Coso
    R Costello
    VJ Bardou
    D Blaise
    L Xerri
    D Sainty
    D Maraninchi
    JA Gastaut
    Bone Marrow Transplantation, 2000, 25 : 35 - 40
  • [6] Aggressive Non-Hodgkin’s LymphomaEconomics of High-Dose Therapy
    Stephen M. Beard
    Lucy Wall
    Louise Gaffney
    Fiona Sampson
    PharmacoEconomics, 2004, 22 : 207 - 224
  • [7] Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?
    Kewalramani T.
    Moskowitz C.H.
    Current Oncology Reports, 2001, 3 (3) : 271 - 278
  • [8] High-dose therapy and transplantation in non-Hodgkin's lymphoma
    Morrison, VA
    Peterson, BA
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 84 - 98
  • [9] High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: The Bologna experience
    Zinzani, PL
    Tani, M
    Gabriele, A
    Gherlinzoni, F
    De Vivo, A
    Ricci, P
    Bandini, G
    Lemoli, RM
    Motta, MR
    Rizzi, S
    Guidice, V
    Zompatori, M
    Stefoni, V
    Alinari, L
    Musuraca, G
    Marchi, E
    Bassi, S
    Conte, R
    Pileri, S
    Tura, S
    Baccarani, M
    LEUKEMIA & LYMPHOMA, 2004, 45 (02) : 321 - 326
  • [10] Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:: Final analysis of the prospective LNH87-2 protocol -: A Groupe d'Etude des Lymphomes de l'Adulte Study
    Haioun, C
    Lepage, E
    Gisselbrecht, C
    Salles, G
    Coiffier, B
    Brice, P
    Bosly, A
    Morel, P
    Nouvel, C
    Tilly, H
    Lederlin, P
    Sebban, C
    Brière, J
    Gaulard, P
    Reyes, F
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 3025 - 3030
12345